Summary & Overview
HCPCS A9520: Technetium tc-99m Tilmanocept, Diagnostic, Up to 0.5 mCi
HCPCS Level II code A9520 covers technetium tc-99m tilmanocept, a diagnostic radiopharmaceutical used primarily for lymphatic mapping and sentinel lymph node imaging. This code captures the agent dose up to 0.5 millicuries and is relevant for nuclear medicine teams, surgical oncology programs, and facility billing departments managing sentinel node procedures. Nationally, accurate coding for radiopharmaceuticals affects reimbursement, inventory control, and clinical documentation for cancer staging workflows.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical use and service settings, common billing modifiers, and what to expect in payer coverage patterns. The publication provides benchmarks and rate reference points where available, summarizes relevant policy updates affecting radiopharmaceutical reimbursement, and situates A9520 within typical nuclear medicine service lines. The content is intended to inform billing staff, practice managers, and clinical teams about coding precision, documentation needs, and payer landscape considerations tied to technetium tc-99m tilmanocept diagnostics.
Billing Code Overview
HCPCS Level II code A9520 describes technetium tc-99m tilmanocept, diagnostic, up to 0.5 millicuries. This code represents a radiopharmaceutical agent used for diagnostic imaging procedures that involve lymphatic mapping and sentinel lymph node identification.
-
Service type: Diagnostic radiopharmaceutical administration for nuclear medicine imaging
-
Typical site of service: Hospital outpatient departments, ambulatory imaging centers, and nuclear medicine suites where diagnostic lymphatic mapping and sentinel node imaging are performed
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 58-year-old woman with clinically node-negative breast cancer scheduled for sentinel lymph node mapping prior to lumpectomy. The nuclear medicine technologist prepares Technetium tc-99m tilmanocept and injects up to 0.5 millicuries per the radiopharmacy protocol. Injection is performed peri-tumorally or periareolarly in the preoperative holding area or nuclear medicine department. Dynamic and static lymphoscintigraphy images are obtained to identify sentinel nodes; the nuclear medicine physician interprets images and marks the skin. In the operating room, the surgical team uses a handheld gamma probe to localize and excise sentinel lymph nodes identified by the radiotracer. Pathology performs frozen section or permanent histology as indicated. Documentation includes radiopharmacy dose record, injection site, time of injection, imaging findings, number and location of sentinel nodes identified, and surgical correlation.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
AS | Left or right side unspecified professional assistant? (Note: AS used by some payors to indicate provider-assistant) | Use when an assistant at surgery is the billing provider under payor-specific rules. |